[1]
|
American Thoracic Society, “Fungal Infection in HIV-Infected Persons,” American Journal of Respiratory and Critical Care Medicine, Vol. 152, No. 2, 1995, pp. 816- 822.
|
[2]
|
D. M. Dixon, M. M. McNeil, M. L. Cohen, B. G. Gellin and J. R. La Montagne, “Fungal Infections—A Growing Threat,” Public Health Reports, Vol. 111, No. 3, 1996, pp. 226-235.
|
[3]
|
J. R. Graybill, “Treatment of Systemic Mycoses in Patients with AIDS,” Archives of Medical Research, Vol. 24, No. 4, 1993, pp. 403-412.
|
[4]
|
N. H. Georgopapadakou and T. J. Walsh, “Human Mycoses—Drugs and Targets for Emerging Pathogens,” Science, Vol. 264, No. 5157, 1994, pp. 371-373.
doi:10.1126/science.8153622
|
[5]
|
R. Y. J. Cartwright, “Anti Fungal Drugs,” Journal of Antimicrobial Chemotherapy, Vol. 1, No. 2, 1975, pp. 141- 162. doi:10.1093/jac/1.2.141
|
[6]
|
J. A. Como and W. E. Dismukes, “Oral Azole Drugs as Systemic Antifungal Therapy,” New England Journal of Medicine, Vol. 330, No. 4, 1994, pp. 263-272.
doi:10.1056/NEJM199401273300407
|
[7]
|
R. A. Fromtling, “Overview of Medically Important Antifungal Azole Derivatives,” Clinical Microbiology Review, Vol. 1, No. 2, 1988, pp. 187-217.
|
[8]
|
C. Barnes and J. Loder, “Structure of Polygodial—A New Sesquiterpene Dialdehyde from Polygonum hydropoper L,” Australian Journal of Chemistry, Vol. 15, No. 2, 1962, pp. 322-327. doi:10.1071/CH9620322
|
[9]
|
S. H. Lee, J. R. Lee, C. S. Lunde and I. Kubo, “In Vitro Anti-Fungal Susceptibilities of Candida albicans and Other Fungal Pathogens to Polygodial, a Sesquiterpene Dialdehyde,” Planta Medica, Vol. 65, No. 3, 1999, pp. 204-208. doi:10.1055/s-1999-13981
|
[10]
|
I. Kubo and M. Taniguchi, “Polygodial, an Antifungal Potentiator,” Jourmal of Natural Products, Vol. 51, No. 1, 1988, pp. 22-29. doi:10.1021/np50055a002
|
[11]
|
S. Sternberg, “The Emerging Fungal Threat,” Science, Vol. 266, No. 5191, 1994, pp. 1632-1634.
doi:10.1126/science.7702654
|
[12]
|
C. W. Norden, H. Wenzel and E. J. Keleti, “Comparison of Techniques for Measurement of in Vitro Antibiotic Synergism,” Journal of Infectious Diseases, Vol. 140, No. 4, 1979, pp. 629-633. doi:10.1093/infdis/140.4.629
|
[13]
|
I. Kubo, K. Fujita and S. H. Lee, “Antifungal Mechanism of Polygodial,” Journal of Agricultural and Food Chemistry, Vol. 49, No. 3, 2001, pp. 1607-1611.
doi:10.1021/jf000136g
|
[14]
|
I. Kubo and S. H. Lee, “Potentiation of Antifungal Activity of Sorbic Acid,” Journal of Agricultural and Food Chemistry, Vol. 46, No. 10, 1998, pp. 4052-4055.
doi:10.1021/jf980174o
|
[15]
|
M. Himejima and I. Kubo, “Fungicidal Activity of Polygodial in Combination with Anethole and Indole against Candida albicans,” Journal of Agricultural and Food Chemistry, Vol. 41, No. 10, 1993, pp. 1776-1779.
doi:10.1021/jf00034a048
|
[16]
|
J. R. Graybill, “The Future of Antifungal Therapy,” Clinical Infectious Diseases, Vol. 22, Supplement 2, 1996, pp. S166-S178.
doi:10.1093/clinids/22.Supplement_2.S166
|
[17]
|
I. Kubo and M. Himejima, “Anethole, a Synergist of Polygodial against Filamentous Microorganisms,” Journal of Agricultural and Food Chemistry, Vol. 39, No. 12, 1991, pp. 2290-2292. doi:10.1021/jf00012a040
|
[18]
|
V. H. Boscche, “Biochemical Targets for Antifungal Azole Derivatives: Hypothesis on the Mode of Action,” In: M. R. McGinnis, Ed., Current Topics in Medical Mycology, Springer-Verlag, New York, 1985, pp. 313-351.
|
[19]
|
M. Taniguchi, Y. Yano, K. Motoba, S. Oi, H. Haraguchi, K. Hashimoto and I. Kubo, “Polygodial-Induced Sensitivity to Rifampicin and Actinomycin D of Saccharomyces cerevisiae,” Agricultural and Biological Chemistry, Vol. 52, No. 7, 1988, pp. 1881-1883.
doi:10.1271/bbb1961.52.1881
|
[20]
|
M. Taniguchi, Y. Yano, E. Tada, K. Ikenishi, S. Oi, H. Haraguchi, K. Hashimoto and I. Kubo, “Mode of Action of Polygodial, an Antifungal Sesquiterpene Dialdehyde,” Agricultural and Biological Chemistry, Vol. 52, No. 6, 1988, pp. 1409-1414. doi:10.1271/bbb1961.52.1409
|
[21]
|
R. Surarit and M. G. Shepherd, “The Effects of Azole and Polyene Antifungals on the Plasma Membrane Enzymes of Candida albicans,” Journal of Medical and Veterinary Mycology, Vol. 25, No. 6, 1987, pp. 403-413.
doi:10.1080/02681218780000491
|
[22]
|
N. H. Georgopapadakou and T. J. Walsh, “Antifungal Agents: Chemotherapeutic Targets and Immunologic Strategies,” Antimicrobial Agents and Chemotherapy, Vol. 40, No. 2, 1996, pp. 279-291.
|
[23]
|
S. Kanazawa, M. Driscoll and K. Struhl, “ATR1, a Saccharomyces cerevisiae Gene Encoding a Transmembrane Protein Required for Aminotriazole Resistance,” Molecular and Cellular Biology, Vol. 8, No. 2, 1988, pp. 664- 673.
|
[24]
|
C. S. Lunde and I. Kubo, “Effect of Polygodial on the Mitochondrial ATPase of Saccharomyces cerevisiae,” Antimicrobial Agents and Chemotherapy, Vol. 44, No. 7, 2000, pp. 1943-1953.
doi:10.1128/AAC.44.7.1943-1953.2000
|
[25]
|
Y. Naito, C. C. Wu, M. G. Seal, F. Gelosa, M. Yoshioka, P. Safran and F. Marotta, “Protective Effect of a Polygodial/Anethole-Containing Natural Product against Candida albicans Gastrointestinal Colonization and Dissemination,” International Medical Journal, Vol. 8, No. 1, 2001, pp. 3-9.
|